Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
December 13, 2004
- JPMA to Amend Charter for Good Corporate Conduct
December 13, 2004
- 3 Qtrs Business Results
December 13, 2004
- BUSINESS NEWS IN BRIEF
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 13, 2004
- Wakamoto: Ethical Drug Div. Posts Declines in Sales, Profits
December 6, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 6, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 6, 2004
- Rohto: Sales Up 6.3% at \32,207 Mil.
December 6, 2004
- Tanabe to License out Its Compounds after PIIa
December 6, 2004
- Dainippon, Sumitomo Pharm to Merge Oct. 1, 2005
December 6, 2004
- Sawai: Flat Sales, Sharp Decline in Profits
December 6, 2004
- Tsumura to Begin Clinical Trial of Kampo Drug from PII in US
December 6, 2004
- Increasing Number of Foreign Companies Aim at Japanese Market
December 6, 2004
- Competition Between Original Drugs and Generics to Intensify: Mr Sawai
December 6, 2004
- Japan's 1st Treatment GL on Ovarian Cancer Published: JSGO
December 6, 2004
- JPMA to Present Proposals on NHI Price System Next Year
December 6, 2004
- Nichiban: Strong Increase in Profits Despite Flat Sales
December 6, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…